All In Biotech

Drug Trial Radar · NCT05116891

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

A Phase 1 / 2 Study of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours

Last checked: Nov 20, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Sep 22, 2021

Primary completion

Jun 23, 2023

Study completion Jun 23, 2023

Sponsor

Lead sponsor
Cantargia ABIndustry
Sponsor type
Industry
First posted
Nov 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).

Conditions

  • Advanced Solid Tumors
  • Colorectal Cancer
  • Non Small Cell Lung Cancer
  • Biliary Tract Cancer

Interventions

  • CAN04 (nadunolimab)Drug

    FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP

  • mFOLFOXDrug

    mFOLFOX/CAN04

  • DTXDrug

    DTX/CAN04

  • G/CDrug

    G/C/CAN04

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of CAN04 in combination with selected standard hemotherapy regimens and to establish MTD and/or RP2D.Time frame: Until 30 days after the last dose of study treatment (EOT visit) in Phase 1
  2. To assess the preliminary efficacy of CAN04 in combination with chemotherapy regimens measured as tumour response.Time frame: Until approximately 3 years after last treatment in Phase 2.

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Institut Bergonie

    Bordeaux, France

  • Centre Eugene Marquis

    Rennes, France

  • EDOG Institut de Cancerologie de l'Ouest - PPDS

    Saint-Herblain, Boulevard Jacques Monod, France

  • Centre Georges François Leclerc

    Dijon, Côte-d'Or, France

  • Hospital Universitari Vall D'Hebron

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.